



EUROHEALTH®
Guiding You to Good Health



Salix® - Saliva Stimulating Lozenge

Fact Sheet for Health Professionals (rev. 2016-11-10)

COMPOSITION ACTIVE INGREDIENTS: Sorbitol, malic acid, sodium citrate, dicalcium phosphate, citric acid.

OTHER COMPONENTS: Propylene glycol, hydrogenated cottonseed oil, silicon dioxide, carboxy methylcellulose.

INDICATIONS For Xerostomia (dry mouth) of any origin. Dry mouth can be caused by many different factors, such as aging alone, smoking, snoring, alcohol consumption, talking for long periods of time, nervousness and stage-fright, being exposed to dust, paints, irritants or dry heating conditions, diseases such as Sjögren's syndrome and other auto-immune disorders, results from medical treatments such as chemotherapy and radiation. Dry mouth is one of the most common side effects from numerous medications, such as diuretics, anti-hypertensives, anti-depressives, antihistamines, tranquilizers, antibiotics, etc.

DOSAGE FORM Tablets

TOXICITY/SIDE EFFECTS None. Safe for long-term use. Does not promote tooth decay. **Salix®** has been tested clinically both in short-term and long-term studies. No increase in enamel erosion has been recorded. No negative side effects.

MODE OF ACTION **Salix®** increases salivation of a reduced salivary gland function through physiological stimulation of the taste buds. Stimulating the individual's own salivary glands into production is more advantageous than using saliva substitutes. The tablets contain sorbitol, fruit acids, salts and a phosphate buffer in a unique composition designed not to damage dental tissue.

SUGGESTED USAGE Allow one tablet to move around slowly, and dissolve in the mouth. Repeat as necessary. In severe dry mouth cases, one tablet per hour is recommended. **Salix®** provides instant relief upon contact.

AVAILABILITY 120 tablets, packed in blisters for convenience and product protection.

PRODUCT HISTORY **Salix®** has been providing relief to Sjögren's syndrome patients in Sweden since 1982. It is currently being used not only by Sjögren's syndrome patients, but by sufferers from dry mouth symptoms world wide. **Salix®** is available as a safe and natural OTC product.

Clinical studies conducted in Sweden, using **Salix®** for six months, showed no measurable changes in microhardness of the enamel nor any changes in the occurrence of S. mutans, lactobacilli, plaque index, or plaque formation rate.

STORAGE Store at or below 20° C in sealed containers in a dry place.



REFERENCES **Axelsson, P., Larsson, U-B.**, "The Saliva Stimulating Tablet SST in Long-Term Clinical Trial", Sweden, 1991.

Björnstrom, M., Axell, T., Birkhed, D., "Comparison Between Saliva Stimulants and Saliva Substitutes in Patients with Symptoms Related to Dry Mouth", (Swed. Dent. J. 14:53-161, 1990), February 1998.

Ericsson, T., "SST Tablet Stimulates Saliva Production in Dryness of the Mouth Without Damaging the Teeth", Faculty of Odont.

Ericsson, T., Lindberg, A., "Clinical Trial of a Saliva Stimulating Tablet", Tandläkartidningen, Sweden, 1982.

Goobar, J., Harju, A., "Clinical Trials of SST - A New Saliva-Stimulating Tablet".

Hamilton-Miller, J.M.T., Senahayake, F., Piggott, K., "A Pilot Study of SALIX®SST" (Salivastimulating Lozenges) In Postirradiation Xerostomia".

Rhodus, N.L., Moller, K., Colby, S., Bereuter, J., "Dysphasia in Patients with Three Different Etiologies of Salivary Gland Dysfunction", ENT Journal, Vol. 74, No. 1, 1995.

DISCLAIMER: *The information presented is intended for educational purposes for health professionals and practitioners. It is obtained from published research and books. It is not intended to be prescriptive, nor replace the care of a licensed health professional in the diagnosis and treatment of illness.*

No part of this publication may be reproduced or transmitted in any form or by any means including electronic, mechanical, photocopying, recording, or information storage system with out written permission from the publisher, except for the inclusion of brief quotations in a review.

CONTACTS

EuroHealth Healthy Aging Project LTD
Mespil House, Sussex Road,
Dublin 4 - Ireland

fax: +353 (0) 1662 5853

email: info@eurohealthproject.com

website: www.eurohealthproject.com

